Clinical trials: Hemoglobin Disorder
Sickle Cell Disease, Thalassemia
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
Background: Sickle cell disease (SCD) is an inherited disorder of the blood. SCD causes red blood cells (RBCs) to die early. This can lead to a shortage of healthy cells.
- Conditions
- Sickle Cell Disease, Thalassemia, Hemoglobinopathy
- Trial name
- NCT06313398
- Testing
- Biotin-labeled red blood cells
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Diabetes Mellitus, Type 2, Rehabilitation
Cardiorespiratory Parameters and Glycated Hemoglobin of Patients With Type 2 Diabetes After a Rehabilitation Program
Cardiovascular autonomic dysfunction reflects the pathophysiology of Diabetes Mellitus in this patient group favors an increase in morbidity and mortality related to cardiovascular events, and for this reason has been one of the…
- Conditions
- Diabetes Mellitus, Type 2, Rehabilitation, Respiratory Therapy
- Trial name
- NCT03094767
- Testing
- Cardiovascular Rehabilitation, Initial and Final assessment
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- União Educacional do Norte
Thalassemia Major
Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut (AUCH)
To assess the effect of different risk factors on the growth parameters of thalassemic patients in Assiut University children Hospital (AUCH) In order to help in decreasing the morbidity and mortality resulting from iron overload…
- Trial name
- NCT05303506
- Testing
- serum ferritin and AST
- Volunteers
- 50 people
- Sponsor
- Assiut University
Sickle Cell Disease
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled patients who have received treatment with OTQ923 for long-term safety and efficacy.
- Trial name
- NCT06155500
- Testing
- OTQ923
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Sickle Cell Disease
Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease
The purpose of this study is to use cardiac magnetic resonance imaging (CMR) and echocardiographic tissue Doppler imaging to demonstrate a unique restrictive cardiomyopathy of sickle cell disease.
- Trial name
- NCT02410811
- Testing
- Cardiac magnetic resonance imaging (CMR)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Anemia
A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching
The aim of this study is to evaluate whether the targeted hemoglobin increment (2 grams per decilitre) in the patient can be predicted from the hemoglobin dose/weight of the blood bag transfused.
- Trial name
- NCT01328262
- Testing
- Calculated red blood cell transfusion, Standard red blood cell transfusion
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Haukeland University Hospital
Blood Disease, Anemia, Sickle Cell
Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II
To establish a link among Chlamydia infection, sickle cell anemia, and stroke risk.
- Conditions
- Blood Disease, Anemia, Sickle Cell, Chlamydia Infections, Cerebrovascular Accident
- Trial name
- NCT00037388
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Thalassemia
Zinc and Diabetes in Patients With Thalassemia: a Pilot Study
The primary aim of this study is to measure zinc status and related proteins in patients with Thalassemia who have or do not have diabetes.
- Trial name
- NCT01772680
- Testing
- Zinc Supplementation
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Diabetes Mellitus, Type 2
Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%
This study is not being conducted in the United States. This is a 52-week extension to a study to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels in…
- Trial name
- NCT00138593
- Testing
- vildagliptin
- Where
- Switzerland
- Volunteers
- 180 people
- Sponsor
- Novartis
Dialysis
Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model
This is a human subject research study conducted in patients undergoing dialysis treatment with darbepoetin alfa at Intermountain Utah Dialysis and Intermountain Medical Center Dialysis Services.
- Trial name
- SMART (NCT05936021)
- Testing
- Algorithm model-based Aranesp doses, Standard of care
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Intermountain Health Care, Inc.
Anemia
An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.
The primary objective of this study is to compare end of study hemoglobin levels between Epoetin alfa at 40,000 units administered subcutaneously once every week and at 80,000 units subcutaneously every two weeks in anemic…
- Trial name
- NCT00210834
- Testing
- epoetin alfa
- Volunteers
- 310 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sickle Cell Anemia, Thalassemia
The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia
The spleen in Sickle Cell Anemia and Sickle Cell Thalassemia is usually enlarged in the first years of life but the immune protection provided is considered insufficient.
- Trial name
- NCT00971698
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- HaEmek Medical Center, Israel
Thalassemia Major
Study to Evaluate the Long- Term Safety and Efficacy of Luspatercept in Subjects Who Received at Least One Dose of Luspatercept in the Compassionate Use Phase
Luspatercept represents the first and only erythroid maturation agent (EMA) approved by the European Commission (EC) and the Food and Drug Administration (FDA) capable of enhancing advanced erythrocyte maturation.
- Trial name
- LUSPA001 (NCT06913634)
- Testing
- Luspatercept (ACE-536)
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia
Anemia, Sickle Cell, Sickling Disorder Due to Hemoglobin S
Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
Chronic blood transfusions are essential supportive care for sickle cell patients at high risk for morbidity and mortality due to stroke. These patients, however, are at risk for iron overload.
- Trial name
- NCT02561312
- Testing
- Rapid manual partial exchange transfusion, Simple Transfusion
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Chattanooga-Hamilton County Hospital Authority
Thalassemia
Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
The definition of Thalassemia Intermedia is not generally accepted and the specific clinical and laboratory characteristics varies between patients.
- Trial name
- NCT01443312
- Testing
- Laboratory analysis.
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- HaEmek Medical Center, Israel
Sickle Cell Disease
Iron Mediated Vascular Disease in Sickle Cell Anemia Patients
The purpose of this research study is to determine the frequency and severity of iron overload in patients with Sickle Cell Anemia and its relationship to blood vessel function.
- Trial name
- NCT01239901
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Hospital Los Angeles
Diabetes Mellitus, Healthy
Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects
Nitric oxide (NO) is a soluble gas, continuously synthesized by the endothelium, that contributes importantly to vasodilator tone of the coronary and systemic circulations by activating guanylyl cyclase in vascular smooth muscle…
- Conditions
- Diabetes Mellitus, Healthy, Hypercholesterolemia, Hypertension
- Trial name
- NCT00001963
- Testing
- hemoglobin-transported nitric oxide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hemoglobinuria, Paroxysmal
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
This study will examine the safety and effectiveness of the experimental drug eculizumab in treating patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare disorder of red blood cells that leads to premature destruction…
- Trial name
- NCT00098280
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
Cohort Study of Sickle Cell Patients Evaluating Analgesic Strategies and Their Consequences
To date, there is no comprehensive data among adults with sickle cell disease concerning the prevalence of consumption of level 2 and 3 analgesics at home and the use of cannabis or CBD for analgesic use.
- Trial name
- DDAM (NCT06650059)
- Testing
- Questionnaire
- Where
- 3 sites in France
- Volunteers
- 257 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age)…
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
- Trial name
- NCT04935879
- Testing
- Inclacumab
- Where
- 58 sites in United States, Brazil and 10 more
- Volunteers
- 241 people
- Sponsor
- Pfizer